Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Cullinan Therapeutics, Inc. (CGEM)
NASDAQ:AMEX Investor Relations:
investorshub.advfn.com/consolidated-gems-inc-cgem-26232
Company Research
Source: GlobeNewswire
Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025 CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025 Zipalertinib pivotal Phase 2b study enrollment completed ahead of schedule; results expected mid-year 2025 CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the third quarter ended September 30, 2024. “We are making meaningful progress in executing our strategic plans for CLN-978 in autoimmune diseases while simultaneously advancing our oncology pipeline,” said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics. “We have secured clearance from the U.S. Food and Drug Administration
Show less
Read more
Impact Snapshot
Event Time:
CGEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEM alerts
High impacting Cullinan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGEM
News
- Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024GlobeNewswire
- Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare ConferenceGlobeNewswire
- Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024GlobeNewswire
- Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
- Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.MarketBeat
CGEM
Earnings
- 8/8/24 - Miss
CGEM
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- CGEM's page on the SEC website